search

Active clinical trials for "Colonic Neoplasms"

Results 271-280 of 1014

Online Education Module to Accurately Classify Polyp Size

Colorectal PolypColonic Neoplasms

Investigators developed an online educational module (ESTIMATE) to teach Gastroenterology (GI) trainees how to estimate polyp size using a snare. Key components include video instruction and real-time feedback incorporated over a 40-item polyp size assessment test. Trainees from GI fellowship programs will be randomized to one of four groups: control (no video, no feedback), video-only, feedback-only, and video + feedback. Participants will classify polyps into one of three size categories:- diminutive (1-5 mm), small (6-9 mm), and large (≥10 mm). Primary outcome is accuracy of polyp size classification [diminutive (1-5 mm), small (6-9 mm), and large (≥10 mm)]. Secondary outcomes include accuracy of exact polyp size (in mm), cumulative accuracy (to plot learning curves), confidence level of polyp size classification, and directionality of inaccuracy (polyp size overestimation vs underestimation).

Active3 enrollment criteria

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic...

Metastatic Colon AdenocarcinomaMetastatic Colorectal Adenocarcinoma26 more

This phase I/II trial studies the side effects and how well encorafenib, binimetinib, and nivolumab work in treating patients with microsatellite stable, BRAFV600E gene-mutated colorectal cancer that has spread to other places in the body (metastatic). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving encorafenib, binimetinib, and nivolumab may work better in treating patients with colorectal cancer compared to standard treatments.

Terminated60 enrollment criteria

The Effect of Unfavorable Histological Features on the Oncological Outcomes of Colon Cancer

Colon Cancer

To explore the effect of unfavorable histological features on the clinical outcomes of patients receiving radical resection of colon cancer.

Active9 enrollment criteria

Study of the Immune Response in Colon Adenocarcinoma

Colon Adenocarcinoma

Duration of each part of the study per patient: Screening: From 1 to 4 weeks Sampling period (blood and tissue): 1 day Follow-up by patient: 60 months Total study duration by patient: 84 months Total inclusion duration: 24 months Total Follow-up duration: 60 months Total study duration: 84 months

Active13 enrollment criteria

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Recurrent Colon CancerRecurrent Rectal Cancer4 more

This phase II trial studies how well Linifanib works in treating patients with advanced, refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Terminated39 enrollment criteria

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small...

Male Breast CancerStage IV Breast Cancer8 more

This phase I trial is studying the side effects and best dose of cediranib maleate when given together with whole brain radiation therapy in treating patients with brain metastases from non-small cell lung cancer. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays and other types of radiation to kill cancer cells and shrink tumors. Giving cediranib maleate together with radiation therapy may kill more tumor cells

Terminated33 enrollment criteria

AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal...

Adenocarcinoma of the ColonAdenocarcinoma of the Rectum4 more

This phase II trial is studying how well AZD0530 works in treating patients with previously treated metastatic colon cancer or rectal cancer. AZD0530 may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

Terminated24 enrollment criteria

The Significance of Sentinel Node Analysis in Colon Cancer

Colon Cancer

This study is for the patient with colon cancer, who is going to have colon cancer surgery. The purpose of this research study is to examine a specific lymph node, called the sentinel node. Lymph nodes are located throughout your body and cancer may spread by means of those lymph nodes. The sentinel node is the one located closest to your tumor. This study will find out if examining the sentinel node can help to predict disease progression. Since the value of this exam is unknown, taking part in this study will not change your clinical care.

Terminated5 enrollment criteria

A Study of MLN8054 in Patients With Advanced Solid Tumors

Breast NeoplasmColon Neoplasm2 more

The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and eliminated from the body; and (4) The levels of MLN8054 in the blood that are needed to inhibit Aurora A kinase.

Terminated28 enrollment criteria

Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer...

Mucinous Adenocarcinoma of the ColonMucinous Adenocarcinoma of the Rectum8 more

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Interferon-gamma may interfere with the growth of tumor cells and slow the growth of the tumor. Combining more than one drug with interferon-gamma may kill more tumor cells. This phase I/II trial is studying the side effects and best dose of giving fluorouracil together with phenylbutyrate, indomethacin, and interferon-gamma and to see how well it works in treating patients with stage IV colorectal cancer

Terminated20 enrollment criteria
1...272829...102

Need Help? Contact our team!


We'll reach out to this number within 24 hrs